When combined with a reduced-calorie diet and increased physical activity, FDA-approved injectable semaglutide has been shown in clinical trials to lead to significant weight loss. In the STEP studies of adults with overweight or obesity, participants taking semaglutide 2.4 mg lost, on average, around 10–15% of their body weight over 68–104 weeks, compared to about 2–3% with placebo. Individual results vary, and weight loss is not guaranteed.